Epidermal growth factor receptor inhibitor therapy-associated erythema dyschromicum perstans-like eruption: a case series.

Epidermal growth factor receptor inhibitor therapy-associated erythema dyschromicum perstans-like eruption: a case series. Br J Dermatol. 2020 Jul 11;: Authors: Ransohoff KJ, Pugliese SB, Zaba LC, Rieger KE, Kwong BY Abstract Epidermal growth factor receptor inhibitors (EGFRi) are used for a variety of solid malignancies. Cutaneous adverse events are common, and include papulopustular eruptions (PPEs) in up to 90% of patients, xerosis, mucositis, paronychia, hypertrichosis, and enhanced radiation dermatitis.1-3 Here, we present a novel case series of eight patients who developed erythema dyschromicum perstans (EDP)-like eruptions while receiving EGFRis. PMID: 32652530 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32652530?dopt=Abstract

Source: The British Journal of Dermatology - July 10, 2020 Category: Dermatology Authors: Ransohoff KJ, Pugliese SB, Zaba LC, Rieger KE, Kwong BY Tags: Br J Dermatol Source Type: research